SPS
CYTK icon

Susquehanna Portfolio Strategies’s Cytokinetics CYTK Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.4M Hold
278,429
– – 0.27% 99
2025
Q4 		$17.7M Hold
278,429
– – 0.27% 97
2025
Q3 		$15.3M Buy
278,429
+14,100
+5% +$581K 0.24% 114
2025
Q2 		$8.73M Buy
+264,329
New +$9.19M 0.19% 156
2024
Q4 		– Sell
-12,701
Closed -$671K – 97
2024
Q3 		$671K Sell
12,701
-20,370
-62% -$1.14M 0.05% 225
2024
Q2 		$1.79M Hold
33,071
– – 0.07% 222
2024
Q1 		$2.32M Hold
33,071
– – 0.05% 309
2023
Q4 		$2.76M Buy
+33,071
New +$1.2M 0.05% 366

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Susquehanna Portfolio Strategies's CYTK Position: Q1 2026 in Review

Susquehanna Portfolio Strategies held its Cytokinetics (CYTK) position steady in Q1 2026 at 278,429 shares worth $18.4M. The position accounts for 0.27% of the portfolio, ranked #99.

Susquehanna Portfolio Strategies first reported a position in CYTK in Q4 2023 and has held it in 8 quarters since. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Susquehanna Portfolio Strategies held 278,429 shares of Cytokinetics worth $18.4M as of Q1 2026.
  • Susquehanna Portfolio Strategies left its Cytokinetics share count unchanged in Q1 2026.
  • Cytokinetics made up 0.27% of Susquehanna Portfolio Strategies's portfolio in Q1 2026, its #99 holding.
  • Susquehanna Portfolio Strategies first reported a position in Cytokinetics in Q4 2023 and has held it in 8 quarters since.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q1 2026, filed 15 May 2026.